Inferior kidney allograft outcomes in patients with de Novo Donor-Specific antibodies are due to acute rejection episodes

Transplantation

Volumn 91, Issue 10, 2011, Pages 1103-1109

  Cooper, James E ^a   Gralla, Jane ^b   Cagle, Linda ^c   Goldberg, Ryan ^a   Chan, Laurence ^a   Wiseman, Alexander C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Children's Hospital Colorado   (United States)

^c Linda Cagle ClinImmune Labs   (United States)

Author keywords

HLA antibody; Kidney transplantation; Rejection

Indexed keywords

HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MISMATCH NEGATIVITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SCREENING TEST;

ACUTE DISEASE; ADULT; ANTIBODIES; COLORADO; FEMALE; FLOW CYTOMETRY; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MASS SCREENING; MIDDLE AGED; PANCREAS TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79955629290     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182139da1     Document Type: Article

References (20)

1. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
2. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652.
3. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
4. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
5. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962.
6. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
7. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
8. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
9. Lee PC, Zhu L, Terasaki PI, et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
10. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438.
11. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up ofHLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
12. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652.
13. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial ofHLAand MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408.
14. Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 2001; 71: 1106.
15. Figueroa J, Fuad SA, Kunjummen BD, et al. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443). Its potential use in discordant xenografting. Transplantation 1993; 55: 1371.
16. Lederer SR, Friedrich N, Banas B, et al. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005; 19: 168.
17. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010; 89: 178.
18. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 433.
19. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403.
20. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.